Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zoccali, C.
Right arrow Articles by Tripepi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zoccali, C.
Right arrow Articles by Tripepi, G.
J Am Soc Nephrol 15:S77-S80, 2004
© 2004 American Society of Nephrology

Supplement Article

Novel Cardiovascular Risk Factors in End-Stage Renal Disease

Carmine Zoccali, Francesca Mallamaci and Giovanni Tripepi

CNR-IBIM, Epidemiologia Clinica e Fisiopatologia delle malattie Renali e dell’Ipertensione Arteriosa, Reggio Calabria, Italy

Correspondence to Carmine Zoccali, CNR-IBIM, Epidemiologia Clinica e Fisiopatologia delle malattie Renali e dell’Ipertensione Arteriosa, Ospedali Riuniti, Via Vallone Petrara, Reggio Calabria 89124, Italy. Phone: 390965397010; Fax: 390965593341; E-mail: carmine.zoccali{at}tin.it

ABSTRACT. Traditional risk factors only in part explain the risk differential between the general population and the population of patients with chronic nephropathies. Uncontrolled hyperphosphatemia and high calcium phosphate product constitute risk factors for cardiovascular calcifications, cardiac ischemia, and adverse cardiovascular outcomes, yet inflammation may be an even more important trigger of vascular calcification than these metabolic derangements. Homocysteine predicts cardiovascular events in ESRD, but evidence that this sulfur amino acid is directly implicated in the high cardiovascular mortality of uremic patients is still lacking. It seems unlikely that Chlamydia pneumoniae is a major risk factor in dialysis patients because the association between anti-Chlamydia antibodies and incident cardiovascular events seems to depend largely on the confounding effect of some traditional risk factors. Oxidative stress and raised plasma concentration of asymmetric dimethylarginine (ADMA) are pervasive in ESRD, and high ADMA in these patients may be at least in part the expression of the high rate of generation of oxidants. ADMA per se seems responsible for a 52% increase in the risk of death and for a 34% increase in the risk of cardiovascular events in dialysis patients.




This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
E. Senol, A. Ersoy, S. Erdinc, E. Sarandol, and M. Yurtkuran
Oxidative stress and ferritin levels in haemodialysis patients
Nephrol. Dial. Transplant., February 1, 2008; 23(2): 665 - 672.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
K. Matsuguma, S. Ueda, S.-i. Yamagishi, Y. Matsumoto, U. Kaneyuki, R. Shibata, T. Fujimura, H. Matsuoka, M. Kimoto, S. Kato, et al.
Molecular Mechanism for Elevation of Asymmetric Dimethylarginine and Its Role for Hypertension in Chronic Kidney Disease
J. Am. Soc. Nephrol., August 1, 2006; 17(8): 2176 - 2183.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
T. Berl and W. Henrich
Kidney-Heart Interactions: Epidemiology, Pathogenesis, and Treatment
Clin. J. Am. Soc. Nephrol., January 1, 2006; 1(1): 8 - 18.
[Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673